MedTrace Logo

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

NCT02867384 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2026-02-19

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).

Conditions

  • Graft vs. Host Disease

Interventions

DRUG

Obinutuzumab

B cell depletion

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Corey Cutler, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2023-11-29
Completion
2024-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02867384 on ClinicalTrials.gov